- Home
- COYA vs ABOS Comparison
COYA vs ABOS Comparison
Compare COYA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.88
HOLD
Current Price
$3.36
Company Overview
Basic Information| Metric | COYA | ABOS |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 155.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | COYA | ABOS |
|---|---|---|
| Price | $4.88 | $3.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $15.80 | $7.50 |
| AVG Volume (30 Days) | 93.6K | ★ 277.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,554,061.00 | N/A |
| Revenue This Year | $69.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $0.86 |
| 52 Week High | $7.75 | $3.50 |
Technical Indicators
Market Signals| Indicator | COYA | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 68.93 |
| Support Level | $4.50 | $1.21 |
| Resistance Level | $5.21 | N/A |
| Average True Range (ATR) | 0.25 | 0.24 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 85.45 | 87.68 |
Price Performance
Historical Comparison COYA
ABOS
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.